Forepont Capital Partners

Okeiro is a technology company specializing in AI-driven solutions for chronic disease and transplant care. It develops predictive algorithms, specifically for kidney transplantation, to assess long-term organ failure risk and personalize treatment plans. The platform aims to enhance clinical decision-making, streamline workflows, and improve patient outcomes by enabling early detection and monitoring.

AlterDiag is a medical diagnostics company that specializes in the development and commercialization of innovative lateral flow immunochromatographic tests. These tests, which use single-chain variable fragment antibodies, are designed to provide rapid, cost-effective, and user-friendly diagnostic solutions for healthcare professionals and patients alike. AlterDiag's products are intended for use in healthcare centers and at home, enabling swift and personalized medical responses.

GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine to combat Streptococcus pneumoniae, a leading cause of severe infections such as pneumonia, bacteremia, meningitis, and otitis media. The company employs a unique gamma-irradiation process that effectively inactivates and kills the bacteria while preserving the integrity of its surface protein antigens. This innovative approach aims to enhance immunity against pneumococcal infections, offering a potentially significant advancement in protecting patients from the serious health risks associated with this bacterial pathogen.

GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine to combat Streptococcus pneumoniae, a leading cause of severe infections such as pneumonia, bacteremia, meningitis, and otitis media. The company employs a unique gamma-irradiation process that effectively inactivates and kills the bacteria while preserving the integrity of its surface protein antigens. This innovative approach aims to enhance immunity against pneumococcal infections, offering a potentially significant advancement in protecting patients from the serious health risks associated with this bacterial pathogen.

Precision Neuroscience, founded in 2021 and based in New York, develops next-generation brain-computer interface technology aimed at treating neurological illnesses. The company's platform is designed to be minimally invasive and safely removable, with the capability to process large amounts of data. This technology enables direct connection between the human brain and artificial intelligence, offering potential breakthrough treatments for the one billion patients worldwide affected by neurological conditions.

Mobius Biomedical plans to bring unprecedented efficiencies to the development and manufacturing of biologics and biosimilars, and reduce their cost by over 90% at commercial scale. The Company has developed new design, new process and new equipment to drastically reduce the capex, opex and facility footprint of manufacturing plants while maintaining the purity, throughput and efficiency at commercial scale.

Precision Neuroscience, founded in 2021 and based in New York, develops next-generation brain-computer interface technology aimed at treating neurological illnesses. The company's platform is designed to be minimally invasive and safely removable, with the capability to process large amounts of data. This technology enables direct connection between the human brain and artificial intelligence, offering potential breakthrough treatments for the one billion patients worldwide affected by neurological conditions.

GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine to combat Streptococcus pneumoniae, a leading cause of severe infections such as pneumonia, bacteremia, meningitis, and otitis media. The company employs a unique gamma-irradiation process that effectively inactivates and kills the bacteria while preserving the integrity of its surface protein antigens. This innovative approach aims to enhance immunity against pneumococcal infections, offering a potentially significant advancement in protecting patients from the serious health risks associated with this bacterial pathogen.

BayBridgeDigital Group LLC, established in 2017, is a New York-based digital advisory and consulting firm with additional offices in Paris and Tel Aviv. It specializes in digital transformation services, including e-commerce, digital marketing, mobile solutions, data analytics, AI, Salesforce integration, and software development. The company serves clients from various industries such as retail, energy, healthcare, and finance, helping them achieve business value through digital solutions. BayBridgeDigital's approach combines design-led strategies with expertise in the Salesforce ecosystem to deliver exceptional results and accelerate digital transformations.